The PET tracers in AD diagnostic imaging started from the radiolabelled glucose analogue [18F] FDG based on dementia-impaired brain glucose metabolism, then progressed into the target-specific small molecules binding to Aβ and tau species with high selectivity over the two past decades, revealing more and more facts behind the AD neurotoxicity in vivo. Here, MAPT is linked to Alzheimer disease.